1087 related articles for article (PubMed ID: 33095513)
1. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
2. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
3. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
[TBL] [Abstract][Full Text] [Related]
4. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
COVID-19 RISk and Treatments (CORIST) Collaboration
Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
[TBL] [Abstract][Full Text] [Related]
5. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system.
Sandhu AT; Kohsaka S; Lin S; Woo CY; Goldstein MK; Heidenreich PA
Am Heart J; 2021 Oct; 240():46-57. PubMed ID: 34126079
[TBL] [Abstract][Full Text] [Related]
7. Effects of Renin-Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials.
Yin J; Wang C; Song X; Li X; Miao M
Am J Hypertens; 2022 May; 35(5):462-469. PubMed ID: 35512430
[TBL] [Abstract][Full Text] [Related]
8. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
[TBL] [Abstract][Full Text] [Related]
9. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
[TBL] [Abstract][Full Text] [Related]
10. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
[TBL] [Abstract][Full Text] [Related]
11. The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
Li M; Wang Y; Ndiwane N; Orner MB; Palacios N; Mittler B; Berlowitz D; Kazis LE; Xia W
PLoS One; 2021; 16(3):e0248652. PubMed ID: 33735262
[TBL] [Abstract][Full Text] [Related]
12. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
Bezabih YM; Bezabih A; Alamneh E; Peterson GM; Bezabhe W
BMC Infect Dis; 2021 Jun; 21(1):527. PubMed ID: 34090358
[TBL] [Abstract][Full Text] [Related]
13. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis.
Zhang X; Yu J; Pan LY; Jiang HY
Pharmacol Res; 2020 Aug; 158():104927. PubMed ID: 32422341
[TBL] [Abstract][Full Text] [Related]
14. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
[TBL] [Abstract][Full Text] [Related]
15. Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19.
Negreira-Caamaño M; Piqueras-Flores J; Martínez-DelRio J; Nieto-Sandoval-Martin-DeLaSierra P; Aguila-Gordo D; Mateo-Gomez C; Salas-Bravo D; Rodriguez-Martinez M; Negreira-Caamaño M
High Blood Press Cardiovasc Prev; 2020 Dec; 27(6):561-568. PubMed ID: 32949380
[TBL] [Abstract][Full Text] [Related]
16. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study).
Mustafic H; Fayssoil A; Josseran L; Ouadahi M; Grimaldi-Bensouda L; Dubourg O; Annane D; Mansencal N
Am J Cardiol; 2021 May; 147():58-60. PubMed ID: 33617818
[TBL] [Abstract][Full Text] [Related]
17. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
Xu J; Huang C; Fan G; Liu Z; Shang L; Zhou F; Wang Y; Yu J; Yang L; Xie K; Huang Z; Huang L; Gu X; Li H; Zhang Y; Wang Y; Hayden FG; Horby PW; Cao B; Wang C
Front Med; 2020 Oct; 14(5):601-612. PubMed ID: 32621202
[TBL] [Abstract][Full Text] [Related]
18. Use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers associated with lower risk of COVID-19 in household contacts.
Armstrong K; Soltoff A; Rieu-Werden M; Metlay J; Haas J
PLoS One; 2021; 16(3):e0247548. PubMed ID: 33651840
[TBL] [Abstract][Full Text] [Related]
19. Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.
Hasan SS; Kow CS; Hadi MA; Zaidi STR; Merchant HA
Am J Cardiovasc Drugs; 2020 Dec; 20(6):571-590. PubMed ID: 32918209
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Grover A; Oberoi M
Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
